ArriVent Expands ADC Pipeline with Exclusive License for MRG007 from Lepu Biopharma

Exclusive License Agreement:
ArriVent BioPharma has entered into an exclusive license agreement with Lepu Biopharma for MRG007, an antibody-drug conjugate (ADC) targeting gastrointestinal (GI) cancers35.

Global Rights:
ArriVent obtains exclusive rights to develop and commercialize MRG007 worldwide outside of Greater China (mainland China, Hong Kong, Macau, and Taiwan)35.

Financial Terms:
Lepu Biopharma will receive a one-time upfront payment and near-term milestone payments totaling $47 million in cash, with potential for up to $1.16 billion in development, regulatory, and sales milestones, and tiered royalties on net sales outside of Greater China35.

Clinical Development:
The first Investigational New Drug (IND) submission for MRG007 is planned for the first half of 2025, with an initial clinical development focus on colorectal, pancreatic, and other GI cancers35.

Pipeline Expansion:
This agreement expands ArriVent’s growing pipeline of next-generation ADCs, furthering its mission to develop novel medicines for cancers with high unmet needs worldwide35.

Sources:

3. https://www.globenewswire.com/news-release/2025/01/22/3013133/0/en/ArriVent-BioPharma-Enters-Exclusive-License-with-Lepu-Biopharma-for-MRG007-an-Antibody-Drug-Conjugate-for-the-treatment-of-Gastrointestinal-Cancers.html

5. https://ir.arrivent.com/news-releases/news-release-details/arrivent-biopharma-enters-exclusive-license-lepu-biopharma